A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos

Lemtrada patients will be more informed and make better decisions from having viewed this series of RRMS videos

Monday, June 22, 2020 - Patients try Lemtrada when they have no other options, and some patients have had mixed experiences with the drug. Patients give Lemtrada a try only after they have given two or more late-stage medications a try and have failed. Lemtrada is an intravenous, disease-modifying therapy (DMT) given to patients that have relapse-remitting multiple sclerosis (RRMS) only after they have agreed in writing with their physicians. The agreement explains in excruciating detail the potential for harm to their health that includes instant death. Some Lemtrada patients feel that they have no other alternative and that they have no choice. When an RRMS patient is contemplating taking such a toxic and life-threatening medication, it is good to get all of the facts so that the patient can make an informed decision.

According to Health Grades.com, Dr. Aaron Boster, MD is a Neurology Specialist in Columbus, OH and has over 18 years of experience in the medical field. Doctor Boster has produced a casual yet highly informative YouTube video while waiting in the car for his son to take a piano lesson. The video outlines the basics of Lemtrada and is a great educational tool for patients that want to know more about their upcoming treatments. Lemtrada attorneys offer a free consultation with no obligation to file a claim.

According to Dr. Bolster, Lemtrada is administered in two doses, one five consecutive day infusions and the other three days, one year apart. A Lemtrada patient is required to see their physician every three months and to have a blood workup and urine testing every month for four years after their first Lemtrada treatment, mostly to check for the early signs of one of the many life-threatening side effects of the drug. A brain MRI is taken at the sixth month to establish a current baseline from which to work. The patient is reimaged annually after that. If during these four years the patient relapses and has a new MS episode or two spots show up on the MRI, the physician will speak with the patient to reassess where they stand and the best course of action going forward, possibly to include the third round of Lemtrada given over three days. Another option would be to do nothing or to switch drugs. The doctor's recommendation depends on the individual patient's RRMS reactions before and after taking Lemtrada. The doctor may recommend a third round of treatments if a patient was performing well and had no new brain lesions. The contrary is true if the patient never really showed benefits relative to Lemtrada's side effects. Statistics show that about half of all Lemtrada patients need a third round of infusion. Around 10% require the fourth course of Lemtrada.

View more of Dr. Bolster's video outlined above at https://www.youtube.com/watch?v=L-7UXhtpNQE. The Dr. has produced a serious of informative MS videos that include the latest information for RRMS patients regarding the risk given the global health pandemic in which we find ourselves.

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
• MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
• Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
• Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
• Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
• People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
• Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
• Lemtrada Patients Have May Have Safer Options | 12/8/2020
• Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
• Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
• Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
• Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
• Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
• Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
• Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
• Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
• Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
• Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
• Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
• RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
• New Information About COVID19 and Taking Lemtrada | 7/16/2020
• The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
• Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
• Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
• Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
• RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
• Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
• Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
• Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
• Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
• Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
• Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
• Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
• Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
• Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
• Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
• Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
• Lemtrada Fears May Be Overdone | 1/30/2020
• Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
• One Last Lemtrada Warning for 2019 | 1/2/2020
• RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
• Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
• Lemtrada Side Effect Awareness Requirements | 12/11/2019
• Lemtrada is serious medication for a serious condition | 11/21/2019
• More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
• RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
• Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
• Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
• Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
• Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
• RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
• Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
• Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
• Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
• Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
• Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
• Lemtrada Patients Report Promising Results | 8/1/2019
• The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
• What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
• Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
• Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
• Treating Multiple Sclerosis From Many Angles | 6/21/2019
• Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
• A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
• A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
• Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
• The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
• Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
• The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
• The Pros and Cons of Lemtrada Therapy | 4/19/2019
• Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
• Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
• MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
• Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
• Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
• Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.